Protagonist Therapeutics Stock: Opt-Out Turned A Biotech Royalty Compounder (NASDAQ:PTGX)
· seekingalpha.com
Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs. Read why PTGX stock is a Buy.
I last covered Protagonist Therapeutics ( PTGX ) about four months ago, in June, when rusfertide was still under priority review and the company held roughly $6...